Long-term use of immunotherapy may be safe for patients with alveolar soft part sarcoma

Long-term adverse events were rare and manageable among patients with alveolar soft part sarcoma (ASPS), which primarily affects adolescents and young adults, who received immunotherapy beyond the standard two years, according to results from a phase II clinical trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.